Search research articles
Contact Us
Filters
Showing results (111-120 of 213) with videos related to
Page
of 22
Sort By:
European Urology
|
May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safety
Himisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Investigational New Drugs
|
April 26, 2014
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
Maha Hussain, Michael A Carducci, Susan Slovin, et al.
Prostate Cancer and Prostatic Diseases
|
February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer
Risa L Wong, Mai T Duong, Catherine M Tangen, et al.
The Oncologist
|
October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial
Neal D Shore, Maha Hussain, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Future Oncology (London, England)
|
October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Urology
|
May 28, 2013
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder
Petros D Grivas, Maha Hussain, Khaled Hafez, et al.
Targeted Oncology
|
September 3, 2021
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Rachel Evans, Neil Hawkins, Pascale Dequen-O'Byrne, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 24, 2025
Effects of food insecurity on infant feeding confidence and practices during the COVID-19 pandemic and its waves
Maha Hussain, Jessica Hyun, Elena Arduin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2014
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen
Maha Hussain, Paul G Corn, M Dror Michaelson, et al.
Page
of 22
Search research articles
Search
Showing results (111-120 of 213) with videos related to
Sort By:
Page
of 22
European Urology
|
May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safety
Himisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Investigational New Drugs
|
April 26, 2014
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
Maha Hussain, Michael A Carducci, Susan Slovin, et al.
Prostate Cancer and Prostatic Diseases
|
February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer
Risa L Wong, Mai T Duong, Catherine M Tangen, et al.
The Oncologist
|
October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial
Neal D Shore, Maha Hussain, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Future Oncology (London, England)
|
October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Urology
|
May 28, 2013
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder
Petros D Grivas, Maha Hussain, Khaled Hafez, et al.
Targeted Oncology
|
September 3, 2021
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Rachel Evans, Neil Hawkins, Pascale Dequen-O'Byrne, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 24, 2025
Effects of food insecurity on infant feeding confidence and practices during the COVID-19 pandemic and its waves
Maha Hussain, Jessica Hyun, Elena Arduin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2014
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen
Maha Hussain, Paul G Corn, M Dror Michaelson, et al.
Page
of 22